Sustained Embolic Protection

June 30, 2020
Disclaimer

This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payors for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
InspireMD is a commercial-stage medical device company focused on stroke prevention in patients with carotid artery disease and treatment of other minimally invasive indications utilizing an integrated embolic protection stent platform.

- The company develops, manufacturers and commercializes a portfolio of embolic protection systems
- MicroNet™, a key differentiator of InspireMD’s commercial products, is revolutionizing the field of vascular stenting
- Today, InspireMD is a global company traded in the NYSE under NSPR
## Our Leadership

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Experience and Roles</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marvin L. Slosman</td>
<td>President and CEO</td>
<td>Mr. Slosman has over 30 years of experience in the medical device industry with focused leadership in commercialization and international market development in both public and privately held companies. He has had senior management roles in a variety of public and privately held companies.</td>
</tr>
<tr>
<td>Craig Shore</td>
<td>CFO</td>
<td>Mr. Shore has over 25 years of experience in financial management in the United States, Europe and Israel. He has served in various senior financial and general management roles at General Electric, Dunn and Bradstreet, Pfizer Pharmaceuticals and Bristol Myers Squibb.</td>
</tr>
<tr>
<td>Paul Stuka</td>
<td>Chairman</td>
<td>Mr. Stuka was named to the Board of Directors in August of 2011 and serves as Chairman of the Board of Directors. Mr. Stuka is a Managing Member of Osiris Partners and a 30-year investment industry veteran.</td>
</tr>
<tr>
<td>Michael Berman</td>
<td>Director</td>
<td>Mr. Berman is a successful entrepreneur within the medical device industry. He joined Scimed in 1986, leading its marketing activities until its merger with Boston Scientific in 1995. From 1995-2000, he served as President of Boston Scientific/Scimed.</td>
</tr>
<tr>
<td>Campbell Rogers, M.D.</td>
<td>Director</td>
<td>Dr. Rogers currently serves as the CMO of HeartFlow, Inc., a private cardiovascular diagnostics company based in California.</td>
</tr>
<tr>
<td>Thomas Kester</td>
<td>Director</td>
<td>Mr. Kester is CFO of Kester Search Group, Inc., a private executive search firm specializing in sales force placement for medical, dental and diagnostic device companies. He spent 28 years at KPMG LLP.</td>
</tr>
</tbody>
</table>
InspireMD Pipeline

Commercial Stage

**Stroke Protection:**

CGuard™ EPS

The CGuard™ Carotid Stent with Embolic Prevention System (EPS) is designed to improve patient safety through sustained embolic protection\(^1,2\) using our MicroNet™ technology.

**Myocardium Protection:**

MGuard™ EPS

The MGuard™ EPS, integrated with MicroNet™, is designed to trap and seal thrombus and ruptured plaque, preventing embolization and optimize flow.

Developing Products

**Carotid Treatment:**

CGuard™ EPS US

CGuard™ AV Shunt / Trans Cervical CAS

**Peripheral Treatment:**

PGuard™ EPS US

**Neuro Treatment:**

NGuard™

References:

Endovascular Procedures: Landscape and InspireMD Potential

**CAD market potential open to endo conversion WW:**

614K procedures in 2018 (estimated)

---

**STILL Awaiting conversion**

<table>
<thead>
<tr>
<th>Disease</th>
<th>Endo</th>
<th>Surgical</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEREBRAL ANEURYSMS</td>
<td>70%</td>
<td>30%</td>
<td></td>
</tr>
<tr>
<td>CORONARY ARTERY DISEASE</td>
<td>77%</td>
<td>23%</td>
<td></td>
</tr>
<tr>
<td>THORACIC/ABDOMINAL AORTIC ANEURYSMS</td>
<td>65%</td>
<td>35%</td>
<td></td>
</tr>
<tr>
<td>PERIPHERAL ARTERIAL DISEASE (PAD)</td>
<td>81%</td>
<td>19%</td>
<td></td>
</tr>
<tr>
<td>CAROTID ARTERY DISEASE</td>
<td>20%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

5. 2017 Health Research International Market Report

---

Already have been converted to endovascular procedures
Stroke is the Second Biggest Cause of Death Globally
An estimated 15 million people suffer from stroke annually

- 6.2 million deaths
- 5 million people left permanently disabled
- $34 billion associated with stroke management in the US alone
- ~85% of all strokes are ischemic strokes, which result from a lack of blood flow to the brain
- Carotid artery disease (CAD) is a major risk factor for stroke
- ~20% of all ischemic strokes are estimated to be caused by CAD (2.2-2.4 million)

3. Center For Disease Control and Prevention – Stroke Facts – 2017
5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861011/
THE PROBLEM: Risks with Existing Approaches to CAD
Surgery (CEA) and conventional Carotid Artery Stenting (CAS) both come with risks

Carotid Endarterectomy (CEA)
Surgical Approach

Risk of complications:
- Myocardial infarction risk\(^1\) (heart attack)
- Cranial nerve injury risk\(^2\) (vertigo, hearing loss, paralysis, etc)
- Esthetic concern

Carotid Artery Stenting (CAS)
Conventional Approach (Bare Stent)

Risk of complications:
- Procedural and post-procedural increase minor stroke risk\(^1\)

Based on the CREST clinical trial data\(^1\), in which only conventional carotid stents were used vs. surgery

\(^1\) CREST Trial: N Engl J Med 2010;363:11-23
\(^2\) Circulation. 2012;125:2256-2264
THE PROBLEM: Risk of Embolism Following Conventional CAS

MRI reveals post-procedural cerebral embolization

Pre-Procedure

90% occlusion of the carotid artery

MRI of a pre-existing white matter infarction (obstruction)

Post-Procedure with Conventional Stent

Successful opening of the carotid artery

MRI reveals new multiple micro-infarcts (obstructions) due to liberation of embolic particles

Cano et al. Rev Bras Cardiol Invasiva 2013; 21(2): 159-64.
**OUR SOLUTION: Proprietary MicroNet™ Technology**

New mesh covered stent that offers superior plaque coverage when compared to conventional stent approaches

**Conventional Stent:**
Bare or dual layer approach, with plaque protrusion risk

**New Covered Stent:**
Stents are covered in MicroNet™

**MicroNet™: an Embolic Prevention System (EPS) for Ultimate Thrombus Protection**

- **Ultrathin flexible mesh** sleeve, designed to expand seamlessly during stent deployment

- Net **captures and locks** thrombus and plaque materials against the arterial wall

- Prevents thrombus or plaque fragments dispersing, **avoids debris** entering the bloodstream

- Acts as a mechanical barrier to prevent **plaque protrusion**
Carotid Solution: Our Well Studied Mesh-Covered Technology

More than 1,500 patients in Clinical Publications and Studies
## Timeline Growth: From Alternative Stent to New Gold Standard

<table>
<thead>
<tr>
<th>YEAR</th>
<th>STUDY</th>
<th>PUBLICATION HIGHLIGHTS</th>
<th>CGUARD™’S STANDING (known &amp; anticipated)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>CARENET 30D</td>
<td>Safety, feasibility &amp; neuroprotection; Neuroprotection over other stents data</td>
<td>☑️ CGuard™ evaluated as new approach to CAS</td>
</tr>
<tr>
<td>2016</td>
<td>PARDIGM 101 30D</td>
<td>All commers population; Excellent clinical results</td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>CASANA</td>
<td>Large surgical center; Excellent clinical results</td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>WISSGOTT</td>
<td>Clinical &amp; mechanical assessment; Mechanical advantages vs competitive stents</td>
<td>☑️ CGuard™ demonstrates best performance in field</td>
</tr>
<tr>
<td>2017</td>
<td>IRON-GUARD 1</td>
<td>Real world multicentric 30d results; Excellent clinical results in multicentric</td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>WISGOTT 10MM</td>
<td>“One size fit all”; Safety &amp; feasibility of a size fit all approach</td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td>IRON-GUARD 1</td>
<td>Real world multicentric 1y results; Excellent long-term results in multicentric</td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td>IRON-GUARD 2 *</td>
<td>Large real world multicentric</td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td>SIBERIA *</td>
<td>Randomized Trial; CGuard neuroprotection vs conventional stents</td>
<td>☑️ CGuard™ demonstrates superiority to other stents</td>
</tr>
<tr>
<td>2021</td>
<td>POLISH VASCULAR REGISTRY *</td>
<td>Large real world multicentric</td>
<td></td>
</tr>
<tr>
<td>2022</td>
<td>OCTOPVS *</td>
<td>OCT comparison CGuard™ vs CEA; to demonstrate CGuard™ superior procedural results than CEA</td>
<td>☑️ CGuard™ demonstrates superiority to surgery</td>
</tr>
<tr>
<td>2022</td>
<td>PARADIGM EXTEND *</td>
<td>Large long-term study for all commers; CGuard™ study of long-term results</td>
<td></td>
</tr>
<tr>
<td>2022</td>
<td>OPTIMA *</td>
<td>IVUS assessment after CGuard™; intended to demonstrate plaque exclusion</td>
<td></td>
</tr>
<tr>
<td>2023</td>
<td>FLOW-GUARD *</td>
<td>Use of CGuard™ as flow diverter in very high-risk patients beyond carotids; Potential new CGuard™ indications</td>
<td>☑️ CGuard™ demonstrates superiority to surgery</td>
</tr>
</tbody>
</table>

* Expected

---

InspireMD
June 30, 2020
When compared with Conventional Stents and Surgery (CEA), CGuard™ trends Superior

- CGuard™ has a superior profile versus historical data on both conventional carotid stents and surgery
- CGuard™ is a next-generation stent supported by a strong and growing body of clinical data
- 7 completed clinical trials and 4 ongoing trials
- NO MAJOR STROKE with CGuard™ (Minor stroke in 17/1,507 pts in 7 studies (1.13%))

**CGuard™ EPS Yields Superior Clinical Outcomes**

**30 Day DSM (Death, Stroke, Myocardial Infarction)**

<table>
<thead>
<tr>
<th></th>
<th>CGuard™</th>
<th>Conventional Stents</th>
<th>Surgery (CEA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 Day DSM</td>
<td>1.86% (1-7)</td>
<td>5.20% (8)</td>
<td>4.50% (8)</td>
</tr>
</tbody>
</table>

2. IRONGUARD II, LINC 2020
4. WISSGOTT I J Endovasc Ther 2019 08. 26:578-582.
5. WISSGOTT II J Endovasc Ther 2017 02. 24:130-137.
8. CREST N Engl J of Med 2010 July 1. 11-23
A Billion Dollar Market Opportunity

Our MicroNet™-covered stents like CGuard™ could become the new gold standard

- 2.2M diagnosed with carotid artery disease (CAD)
- 2017: ~600,000 patients with high grade carotid stenosis (HGCS) required interventions for CAD
- At present, ~80% are surgically treated CEA
- At a price of $1,650 per stent, the addressable market is estimated to be more than $1 billion

2017 Health Research International Market Report

CAS = Carotid Artery Stenting
CEA = Carotid Endarterectomy
• Active Selling in 39 Countries

• Over 90% of sales are through channel partners / distributors

• Short Term Expansion Brazil and France

• New countries development include Japan, S Korea and China

• IDE Approval progressing with FDA; targeting initiation of US trial in 2021 (subject to FDA approval)
Our Lead Product, CGuard™ - Advancing Rapidly

31% growth of CGuard™ portfolio in Q4 2019

18,000 Total protected stents sold to date with excellent clinical results

CGuard™ has potential to become the new standard-of-care for carotid indications

*Achieved clinical milestones; neuroprotective vs other carotid artery stenting (SERBIA)
Our Advancement Roadmap / Milestones

Key Value Drivers and Strategic Pathways

**Driving Commercial Focus**

- Launch CGuard™ in U.S. & China
- Advance AV Shunt (Reverse Flow)
- Expanded indications for MicroNet™

**Demonstrate Commercially Driven Market Awareness, Capability, Results & Growth**

- Demonstrate Superiority of CGuard™ in CAS
- Grow above market in those served
- Launch CGuard™ in Brazil
- Complete CGuard™ IDE Approval for U.S.
- Initiate CGuard™ registration in China with Partner
- Advance distribution options in Japan

**Transform Carotid Artery Disease Care Globally**

- Drive share leadership for Protected CAS in EU
- Growth in South American Markets
- Significant Podium Presence
- Plan to Enroll CGuard™ U.S. IDE
- Plan to Enroll CGuard™ China Clinical Trial

**Expand Broad Global Embolic Protection Indications**

- 2019
- 2020
- 2021
- 2022 and Beyond
## Our Robust Intellectual Property Portfolio

Proprietary platform technology supported by IP

<table>
<thead>
<tr>
<th>Patent Rights</th>
<th>Issued</th>
<th>Allowed</th>
<th>Pending</th>
</tr>
</thead>
<tbody>
<tr>
<td>USA</td>
<td>14</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Rest of World</td>
<td>33</td>
<td>4</td>
<td>14</td>
</tr>
</tbody>
</table>

- InspireMD will continue to strengthen and broaden its patent protection globally to enable future pipeline products
Our Business and Market Development

Strategic Targets for Merger or Acquisition

Synergy
Silk Road - Comparison

- Ticker SILK
- $120 Million IPO ($20 per share) – April 2019
- Valuation at time of IPO – $600 Million
- Current Stock Price - $37.46
- Market Value today - $1.3 Billion
- Revenue in 2019 - $63.4 Million (United States Only)

Silk Road Stock Performance since IPO
### Summary Financials

<table>
<thead>
<tr>
<th>NYSE AMERICAN</th>
<th>NSPR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Price (6/29/20):</td>
<td>$0.47</td>
</tr>
<tr>
<td>Average volume:</td>
<td>3.6 M</td>
</tr>
<tr>
<td>Shares outstanding (6/29/20):</td>
<td>33.4 M</td>
</tr>
<tr>
<td>Shares outstanding including full conversion of preferred shares and prefunded warrants (6/29/20):</td>
<td>35.6 M</td>
</tr>
<tr>
<td>Market capitalization including full conversion of preferred shares and prefunded warrants (6/29/20):</td>
<td>$16.7 M</td>
</tr>
<tr>
<td>Cash (3/31/20) – excludes June 2020 fund raising</td>
<td>$3.1 M</td>
</tr>
</tbody>
</table>
## Company Highlights

| CGuard™ EPS | Enabling a paradigm shift (CAS) in the treatment of carotid artery disease and stroke prevention  
Breakthrough platform: Highly differentiated, with strong support from leading clinicians  
MicroNet™ technology that is elegantly simple, proprietary and easily leveraged to other medical devices |
| Benefits Demonstrated in Multiple Trials | Clinical evidence / data driven: 7 clinical trials completed with >1,500 patient procedures and 4 ongoing clinical trials  
Differentiation versus conventional carotid stents and surgery with both short- and long-term results  
Outcomes based: No device related major adverse events. No major strokes or deaths related to device.  
Sustainable results: Long term benefit reported in all-comer population |
| Commercial Growth | Expanding existing footprint: Deeper penetration within key markets (18,000 devices sold to date)  
Results: 2019 CGuard™ EPS sales increased 31% Q4/Q4  
Commercial model development: Evaluating opportunities to go direct in key markets |
| $1B Global Market Opportunity | Expansion into OUS markets: Near term: Brazil; strategic partners discussions in Japan and China  
United States:  
• IDE FDA submission for CGuard™ EPS July 2019; Filed re-submission May 2020  
• Critical step in commencing human trial in the USA |
| Capital Structure | Recapitalized the company to clean up the capital structure and prepare for growth  
Capital use focused on commercial execution and pipeline |
| Pipeline and Strategic Opportunities | Leverage MicroNet™ into other pipeline opportunities in other neurovascular and peripheral techniques and treatments  
Proactively seek synergistic product opportunities  
Add BD resources to effectively assess inbound queries and implement a more focused and proactive BD strategy |
Thank you